pyrroles has been researched along with midostaurin in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.00) | 18.2507 |
| 2000's | 7 (35.00) | 29.6817 |
| 2010's | 9 (45.00) | 24.3611 |
| 2020's | 3 (15.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, FB; Davis, PJ; Lin, HY; Thacorf, HR | 1 |
| Bodis, S; Hofstetter, B; Pruschy, M; Riesterer, O; Tenzer, A; Vuong, V; Zingg, D | 1 |
| Kiyoi, H | 1 |
| Berdel, WE; Müller-Tidow, C; Serve, H; Tickenbrock, L | 1 |
| von Mehren, M | 1 |
| Duyster, J; Grundler, R; Kancha, RK; Peschel, C | 1 |
| Bui, B; Italiano, A | 1 |
| Ehninger, G; Illmer, T | 1 |
| Levis, M; Murphy, KM; Pratz, KW; Rajkhowa, T; Sato, T; Stine, A | 1 |
| Ashman, LK; Griffith, R; Mashkani, B | 1 |
| Chabner, BA; Fathi, AT | 1 |
| Fiedler, W; Wellbrock, J | 1 |
| Bhatt, L; Chang, CJ; Cotter, TG; Dickinson, BC; Gough, DR; Naughton, R; Stanicka, J; Woolley, JF | 1 |
| Albers, C; Duyster, J; Illert, AL; Leischner, H; Peschel, C; Verbeek, M; von Bubnoff, N; Yu, C | 1 |
| Bennett, KL; Borgdorff, V; Breitwieser, FP; Colinge, J; Gridling, M; Müller, AC; Rix, U; Superti-Furga, G; Wagner, C; Wagner, SN; Winter, GE | 1 |
| Apsel Winger, B; Cortopassi, WA; Ding, L; Esteve-Puig, R; Garrido Ruiz, D; Jacobson, MP; Jang, K; Leyte-Vidal, A; Shah, NP; Zhang, N | 1 |
| Adamia, S; Buhrlage, SJ; Case, AE; Dubreuil, P; Gokhale, PC; Gray, N; Griffin, JD; Letard, S; Liu, X; Meng, C; Sattler, M; Stone, RM; Tiv, HL; Wang, J; Weisberg, E; Yang, J | 1 |
| George, TI; Gotlib, J; Reiter, A | 1 |
| Gotlib, J; Shomali, W | 1 |
| Iannazzo, S; Pilkington, H; Roskell, N; Smith, S | 1 |
9 review(s) available for pyrroles and midostaurin
| Article | Year |
|---|---|
[Possibility of targeting FLT3 kinase for the treatment of leukemia].
Topics: Animals; Antibodies, Monoclonal; Benzoquinones; Carbazoles; Drug Design; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Lactams, Macrocyclic; Leukemia; Mutation; Piperazines; Pyrroles; Quinazolines; Quinones; Rifabutin; Staurosporine; Sunitinib | 2005 |
Emerging Flt3 kinase inhibitors in the treatment of leukaemia.
Topics: Animals; Antineoplastic Agents; Carbazoles; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Therapy, Combination; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Pyrroles; Signal Transduction; Staurosporine | 2006 |
Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Everolimus; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunosuppressive Agents; Indoles; Niacinamide; Oligonucleotides; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sirolimus; Staurosporine; Sunitinib; Thiazoles | 2006 |
[Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Proteins; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperazines; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib; Staurosporine; Sunitinib; Thiazoles | 2008 |
FLT3 kinase inhibitors in the management of acute myeloid leukemia.
Topics: Benzenesulfonates; Carbazoles; Clinical Trials as Topic; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib | 2007 |
Clinical experience with antiangiogenic therapy in leukemia.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Humans; Indoles; Lenalidomide; Leukemia; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib; Thalidomide; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2011 |
New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis.
Topics: Animals; Chromosome Aberrations; Hematopoietic Stem Cell Transplantation; Humans; Mastocytosis, Systemic; Mutation; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrazoles; Pyrroles; Staurosporine; Triazines | 2020 |
Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors.
Topics: Cell Proliferation; Enzyme Inhibitors; Female; Humans; Mast Cells; Mastocytosis, Systemic; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrazoles; Pyrroles; Staurosporine; Triazines | 2021 |
Indirect treatment comparisons of avapritinib versus midostaurin for patients with advanced systemic mastocytosis.
Topics: Humans; Mastocytosis, Systemic; Pyrazoles; Pyrroles; Staurosporine; Triazines | 2022 |
11 other study(ies) available for pyrroles and midostaurin
| Article | Year |
|---|---|
Potentiation by thyroxine of interferon-gamma-induced antiviral state requires PKA and PKC activities.
Topics: Animals; Calmodulin; Carbazoles; Cyclic AMP; Cyclic AMP-Dependent Protein Kinase Type II; Cyclic AMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Estrenes; HeLa Cells; Humans; Indoles; Interferon-gamma; L Cells; Mice; Protein Kinase C; Pyrroles; Pyrrolidinones; Rhabdoviridae Infections; Staurosporine; Sulfonamides; Tetradecanoylphorbol Acetate; Thyroxine; Time Factors; Vesicular stomatitis Indiana virus; Viral Interference | 1996 |
Novel radiosensitizers for locally advanced epithelial tumors: inhibition of the PI3K/Akt survival pathway in tumor cells and in tumor-associated endothelial cells as a novel treatment strategy?
Topics: Cell Survival; Combined Modality Therapy; Down-Regulation; Endothelial Cells; Enzyme Inhibitors; ErbB Receptors; Neoplasm Proteins; Neoplasms, Glandular and Epithelial; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phthalazines; Protein Kinase C; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyridines; Pyrimidines; Pyrroles; Radiation-Sensitizing Agents; Receptors, Vascular Endothelial Growth Factor; Staurosporine | 2004 |
Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.
Topics: Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Staurosporine; Sunitinib | 2007 |
FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.
Topics: Alleles; Antineoplastic Agents; Benzenesulfonates; Benzothiazoles; Carbazoles; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Furans; Humans; Indazoles; Indoles; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Pyridines; Pyrroles; Sorafenib; Staurosporine; Sunitinib | 2010 |
Colony stimulating factor-1 receptor as a target for small molecule inhibitors.
Topics: Benzamides; Binding Sites; Carbazoles; Computer Simulation; Dasatinib; Drug Design; Furans; Humans; Hydrogen Bonding; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor; Staurosporine; Sunitinib; Thiazoles | 2010 |
FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations.
Topics: Antineoplastic Agents; Benzothiazoles; Carbazoles; Clinical Trials as Topic; Cytokines; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid, Acute; Phenylurea Compounds; Pyrroles; Staurosporine; Sunitinib; Tandem Repeat Sequences | 2011 |
H2O2 production downstream of FLT3 is mediated by p22phox in the endoplasmic reticulum and is required for STAT5 signalling.
Topics: Benzoxazoles; Cell Line, Tumor; Endoplasmic Reticulum; Fluorescent Dyes; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Hydrogen Peroxide; Imidazoles; Leukemia, Myeloid, Acute; Mitochondria; Mutation; NADPH Oxidases; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-pim-1; Pyrroles; RNA, Small Interfering; Signal Transduction; STAT5 Transcription Factor; Staurosporine; Triazoles | 2012 |
The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib.
Topics: Antineoplastic Agents; Benzothiazoles; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Phenylurea Compounds; Pyrroles; Staurosporine; Sunitinib | 2013 |
A chemical biology approach identifies AMPK as a modulator of melanoma oncogene MITF.
Topics: AMP-Activated Protein Kinases; Blotting, Western; Cell Line; Cell Survival; Chromatography, Liquid; Enzyme Inhibitors; Fluorescent Antibody Technique; Humans; Indoles; Mass Spectrometry; Melanocytes; Melanoma; Microphthalmia-Associated Transcription Factor; Oncogenes; Pyrroles; RNA Interference; RNA, Small Interfering; Staurosporine; Sunitinib; Transfection | 2014 |
ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KIT.
Topics: Antineoplastic Agents; Cell Line; Drug Resistance, Neoplasm; Exons; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrazoles; Pyrroles; Staurosporine; Triazines | 2019 |
Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.
Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Cell Line, Tumor; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Hematologic Neoplasms; Humans; Mutant Proteins; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-cbl; Proto-Oncogene Proteins c-kit; Pyrazines; Pyrazoles; Pyrroles; Sorafenib; Staurosporine; Triazines | 2019 |